Chromosome band 16q22-linked familial AML: Exclusion of candidate genes, and possible disease risk modification by NQO1 polymorphisms

Genes Chromosomes and Cancer

Volumn 41, Issue 3, 2004, Pages 278-282

  Escher, Robert ^a   Jones, Antonia ^a   Hagos, Fitsum ^b   Carmichael, Catherine ^a   Horwitz, Marshall ^c   Olopade, Olufunmilayo I ^b   Scott, Hamish S ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CBFB GENE; CHROMOSOME 16Q; CHROMOSOME BAND; FAMILIAL DISEASE; GENE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MULTIGENE FAMILY; NQO1 GENE; PRIORITY JOURNAL; RUNX1 GENE;

CHROMOSOME BANDING; CHROMOSOMES; CHROMOSOMES, HUMAN, PAIR 16; DNA-BINDING PROTEINS; GENES, DOMINANT; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LINKAGE (GENETICS); NAD(P)H DEHYDROGENASE (QUINONE); NFATC TRANSCRIPTION FACTORS; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; RISK; RISK FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 4644289994     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20084     Document Type: Article

References (30)

1. Crans HN, Sakamoto KM. 2001. Transcription factors and translocations in lymphoid and myeloid leukemia. Leukemia 15:313-331.
2. Escher R, Hagos F, Michaud J, Sveen L, Horwitz M, Olopade OI, Scott HS. 2004. No evidence for core-binding factor CBFβ as a leukemia predisposing factor in chromosome 16q22-linked familial AML. Leukemia 18:881.
3. Filippova GN, Qi CF, Ulmer JE, Moore JM, Ward MD, Hu YJ, Loukinov DI, Pugacheva EM, Klenova EM, Grundy PE, Feinberg AP, Cleton-Jansen A, Moerland EW, Cornelisse CJ, Suzuki H. Komiya A, Lindblom A, Dorion-Bonnet F, Neiman PE, Morse III HC, Collins SJ, Lobanenkov W. 2002. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res 62:48-52.
4. Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. 1998. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 8:305-313.
5. Gao Q, Horwitz M, Roulston D, Hagos F, Zhao N, Freireich EJ, Golomb HM, Olopade OI. 2000. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer 28:164-172.
6. Graef IA, Chen F, Crabtree GR. 2001. NFAT signaling in vertebrate development. Curr Opin Genet Dev 11:505-512.
7. Hajra KM, Fearon ER. 2002. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34:255-268.
8. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. 2002. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21:3414-3421.
9. Horwitz M. 2002. The genetics of hematopoietic malignancy. In: King RA RJ, Motulsky AG. editors. The genetic basis of common disease. New York: Oxford University Press, p 749-776.
10. Horwitz M, Sabath DE, Smithson WA, Radich J. 1996. A family inheriting different subtypes of acute myelogenous leukemia. Am J Hematol 52:295-304.
11. Horwitz M, Benson KF, Li FQ, Wolff J, Leppert MF, Hobson L, Mangelsdorf M, Yu S, Hewett D, Richards RI, Raskind WH. 1997. Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2. Am J Hum Genet 61:873-881.
12. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. 2002. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 4:540-544.
13. Komatsu N, Takeuchi S, Ikezoe T, Tasaka T, Hatta Y, Machida H, Williamson IK, Bartram CR, Koeffler HP, Taguchi H. 2000. Mutations of the E2F4 gene in hematological malignancies having microsatellite instability. Blood 95:1509-1510.
14. Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, Smith MT. 1999. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94:803-807.
15. Leroy H, Roumier C, Grardel-Duflos N, Macintyre E, Lepelley P, Fenaux P, Preudhomme C. 2002. Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes. Blood 99:3848-3850.
16. Long DJ, 2nd. Gaikwad A, Multani A, Pathak S, Montgomery CA, Gonzalez FJ, Jaiswal AK. 2002. Disruption of the NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res 62:3030-3036.
17. Look AT. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
18. Melki JR, Vincent PC, Brown RD, Clark SJ. 2000. Hypermethylation of E-cadherin in leukemia. Blood 95:3208-3213.
19. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind VVH, Rossier C, Antonarakis SE, Israels S, McNicol A, Weiss H, Horwitz M, Scott HS. 2002. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 99:1364-1372.
20. Michaud J, Scott HS, Escher R. 2003. AML1 interconnected pathways of leukemogenesis. Cancer Invest 21:105-136.
21. Moran JL, Siegel D, Ross D. 1999. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Nad Acad Sci USA 96:8150-8155.
22. Moriyama H, Sasamoto H, Kambara T, Matsubara N, Ikeda M, Baba S, Meltzer SJ, Lynch HT, Shimizu K, Tanaka N. 2002. E2F-4 mutation in hereditary non-polyposis colorectal cancer. J Exp Clin Cancer Res 21:185-189.
23. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330.
24. Pan SS, Han Y, Farabaugh P, Xia H. 2002. Implication of alternative splicing for expression of a variant NAD(P)H:quinone oxidoreductase-1 with a single nucleotide polymorphism at 465C>T. Pharmacogenetics 12:479-488.
25. Rempel RE, Saenz-Robles MT, Storms R, Morham S, Ishida S, Engel A, Jakoi L, Melhem MF, Pipas JM, Smith C, Nevins JR. 2000. Loss of E2F4 activity leads to abnormal development of multiple cellular lineages. Mol Cell 6:293-306.
26. Smith MT, Wang Y, Kane E, Rollinson S, Wiemels JL, Roman E, Roddam P, Cartwright R, Morgan G. 2001. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 97:1422-1426.
27. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23:166-175.
28. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996a. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Nad Acad Sci USA 93:3444-3449.
29. Wang Q, Stacy T, Miller JD, Lewis AF, Gu TL, Huang X, Bushweller JH, Bories JC, Alt FW, Ryan G, Liu PP. Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996b. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 87:697-708.
30. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF. 1999. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 59:4095-4099.